Results of a 2-Arm, Phase 2 Clinical Trial Using Post-Transplantation Cyclophosphamide for the Prevention of Graft-Versus-Host Disease in Haploidentical Donor and Mismatched Unrelated Donor Hematopoietic Stem Cell Transplantation

BACKGROUND: High-dose, post-transplantation cyclophosphamide (PTCy) to prevent graft-versus-host disease (GVHD) has improved outcomes in haploidentical (HAPLO) stem cell transplantation (SCT). However, it remains unclear whether this strategy is effective in SCT from 1-antigen human leukocyte antige...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer
Autors principals: Gaballa, Sameh, Ge, Isabell, Fakih, Riad El, Brammer, Jonathan E., Kongtim, Piyanuch, Tomuleasa, Ciprian, Wang, Sa A., Lee, Dean, Petropoulos, Demetrios, Cao, Kai, Rondon, Gabriela, Chen, Julianne, Hammerstrom, Aimee, Lombardi, Lindsey, Alatrash, Gheath, Korbling, Martin, Oran, Betul, Kebriaei, Partow, Ahmed, Sairah, Shah, Nina, Rezvani, Katayoun, Marin, David, Bashir, Qaiser, Alousi, Amin, Nieto, Yago, Qazilbash, Muzaffar, Hosing, Chitra, Popat, Uday, Shpall, Elizabeth J., Khouri, Issa, Champlin, Richard E., Ciurea, Stefan O.
Format: Artigo
Idioma:Inglês
Publicat: 2016
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5459484/
https://ncbi.nlm.nih.gov/pubmed/27404668
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.30180
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars